Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice.
The myeloperoxidase (MPO)-hydrogen peroxide-halide system is an efficient oxygen-dependent antimicrobial component of polymorphonuclear leukocyte (PMN)-mediated host defense. However, MPO deficiency results in few clinical consequences indicating the activation of compensatory mechanisms. Here, we determined possible mechanisms protecting the host using MPO(-/-) mice challenged with live gram-negative bacterium Escherichia coli. We observed that MPO(-/-) mice unexpectedly had improved survival compared with wild-type (WT) mice within 5-12 h after intraperitoneal E. coli challenge. Lungs of MPO(-/-) mice also demonstrated lower bacterial colonization and markedly attenuated increases in microvascular permeability and edema formation after E. coli challenge compared with WT. However, PMN sequestration in lungs of both groups was similar. Basal inducible nitric oxide synthase (iNOS) expression was significantly elevated in lungs and PMNs of MPO(-/-) mice, and NO production was increased two- to sixfold compared with WT. Nitrotyrosine levels doubled in lungs of WT mice within 1 h after E. coli challenge but did not change in MPO(-/-) mice. Inhibition of iNOS in MPO(-/-) mice significantly increased lung edema and reduced their survival after E. coli challenge, but iNOS inhibitor had the opposite effect in WT mice. Thus augmented iNOS expression and NO production in MPO(-/-) mice compensate for the lack of HOCl-mediated bacterial killing, and the absence of MPO-derived oxidants mitigates E. coli sepsis-induced lung inflammation and injury.
Brovkovych
Viktor
V
Department of Pharmacology, University of Illinois College of Medicine, 835 S. Wolcott, Chicago, Illinois 60612, USA.
Gao
Xiao-Pei
XP
Ong
Evan
E
Brovkovych
Svitlana
S
Brennan
Marie-Luise
ML
Su
Xiao
X
Hazen
Stanley L
SL
Malik
Asrar B
AB
Skidgel
Randal A
RA
D000818:Animals; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015971:Gene Expression Regulation, Enzymologic / Q000235:genetics; D008168:Lung / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D055370:Lung Injury; D051379:Mice; D018345:Mice, Knockout; D009504:Neutrophils / Q000201:enzymology* / Q000473:pathology; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000235:genetics; D052247:Nitric Oxide Synthase Type II / Q000096:biosynthesis* / Q000235:genetics; D016877:Oxidants / Q000378:metabolism; D009195:Peroxidase / Q000235:genetics / Q000378:metabolism*; D011654:Pulmonary Edema / Q000201:enzymology* / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D018805:Sepsis / Q000201:enzymology* / Q000235:genetics / Q000382:microbiology / Q000473:pathology; D014443:Tyrosine / Q000031:analogs & derivatives / Q000235:genetics / Q000378:metabolism
D016877:Oxidants; D009569:Nitric Oxide; C002744:3-nitrotyrosine; D014443:Tyrosine; D009195:Peroxidase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse